Recent Finacing
Recent Raise
Retrophin is a New York biotechnology firm developing therapeutics for rare diseases, advancing a pipeline including RE-021 (dual angiotensin and endothelin receptor antagonist for FSGS) and RE-001 for DMD.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor